Discovery of new selective glucocorticoid receptor agonist leads

被引：10
|
作者：
Berger, Markus [1 ]
Rehwinkel, Hartmut [1 ]
Schmees, Norbert [1 ]
Schaecke, Heike [2 ]
Edman, Karl [3 ]
Wissler, Lisa [3 ]
Reichel, Andreas [4 ]
Jaroch, Stefan [5 ]
机构：
[1] Bayer Pharma AG, Med Chem Berlin, Candidate Generat & External Innovat, Drug Discovery, D-13353 Berlin, Germany
[2] Bayer Pharma AG, Gynecol Therapies Berlin, Global Therapeut Res, Drug Discovery, D-13353 Berlin, Germany
[3] AstraZeneca, Discovery Sci, Innovat Med & Early Dev Biotech Unit, Pepparedsleden 1, S-43183 Molndal, Sweden
[4] Bayer Pharma AG, Res Pharmacokinet, Early Dev, Drug Discovery, D-13353 Berlin, Germany
[5] Bayer Pharma AG, Global External Innovat & Alliances, Candidate Generat & External Innovat, Drug Discovery, D-13353 Berlin, Germany
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2017年 / 27卷 / 03期
关键词：
Glucocorticoid; SEGRA; Transrepression; Transactivation; Tetrahydronaphthalene; Amino alcohol; LIGAND-BINDING DOMAIN; MINERALOCORTICOID RECEPTOR; INFLAMMATORY RESPONSES; CRYSTAL-STRUCTURE; MECHANISMS; IDENTIFICATION; THERAPY; RU-486; SKIN;
D O I：
10.1016/j.bmcl.2016.12.047
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
We report on the discovery of two new lead series for the development of glucocorticoid receptor agonists. Firstly, the discovery of tetrahydronaphthalenes led to metabolically stable and dissociated compounds. Their binding mode to the glucocorticoid receptor could be elucidated through an X-ray structure. Closer inspection into the reaction path and analyses of side products revealed a new amino alcohol series also addressing the glucocorticoid receptor and demonstrating strong anti-inflammatory activity in vitro. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码：437 / 442
页数：6
相关论文
共 50 条
  • [11] Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects
    Schäcke, H
    Schottelius, A
    Döcke, WD
    Strehlke, P
    Jaroch, S
    Schmees, N
    Rehwinkel, H
    Hennekes, H
    Asadullah, K
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (01) : 227 - 232
  • [12] Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist
    Erickson-Miller, CL
    DeLorme, E
    Tian, SS
    Hopson, CB
    Stark, K
    Giampa, L
    Valoret, EI
    Duffy, KJ
    Luengo, JL
    Rosen, J
    Miller, SG
    Dillon, SB
    Lamb, P
    EXPERIMENTAL HEMATOLOGY, 2005, 33 (01) : 85 - 93
  • [13] Identification of the selective glucocorticoid receptor agonist Mapracorat as potential new drug for chronic wound therapy
    Wolff-Winiski, B.
    Schoefmann, N.
    Doerfler, P.
    Cabral, G.
    Stuetz, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S286 - S286
  • [14] Recent developments in the discovery of selective glucocorticoid receptor modulators (SGRMs)
    Hudson, Andrew R.
    Roach, Steven L.
    Higuchi, Robert I.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (09) : 750 - 765
  • [15] Discovery of selective glucocorticoid receptor modulator MK-5932
    Bungard, Christopher J.
    Hartman, George D.
    Manikowski, Jesse J.
    Perkins, James J.
    Bai, Chang
    Brandish, Philip E.
    Euler, Danielle H.
    Hershey, James C.
    Schmidt, Azriel
    Fang, Yulin
    Norcross, Ryan T.
    Rushmore, Tom H.
    Thompson, Charles D.
    Meissner, Robert S.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (24) : 7374 - 7386
  • [16] Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening
    Gerber, Anthony N.
    Masuno, Kiriko
    Diamond, Marc I.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (12) : 4929 - 4934
  • [17] Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists
    Morgan, BP
    Swick, AG
    Hargrove, DM
    LaFlamme, JA
    Moynihan, MS
    Carroll, RS
    Martin, KA
    Lee, E
    Decosta, D
    Bordner, J
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (12) : 2417 - 2424
  • [18] Dissociation of transactivation from transrepression activity by a selective glucocorticoid receptor agonist (SEGRA) leads to separation of therapeutic effects from side effects
    Schäcke, H
    Schottelius, A
    Döcke, WD
    Strehlke, P
    Jaroch, S
    Schmees, N
    Rehwinkel, H
    Hennekes, H
    Asadullah, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (02)
  • [19] Dissociation of transactivation from transrepression activity by a selective glucocorticoid receptor agonist (SEGRA) leads to separation of therapeutic effects from side effects
    Schaecke, H
    Schottelius, A
    Doecke, WD
    Strehlke, P
    Jaroch, S
    Schmees, N
    Rehwinkel, H
    Hennekes, H
    Asadullah, K
    CLINICAL IMMUNOLOGY, 2005, 115 : S255 - S255
  • [20] Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist
    Brown, Angus R.
    Bosies, Michael
    Cameron, Helen
    Clark, John
    Cowley, Angela
    Craighead, Mark
    Elmore, Moira A.
    Firth, Alistair
    Goodwin, Richard
    Goutcher, Susan
    Grant, Emma
    Grassie, Morag
    Grove, Simon J. A.
    Hamilton, Niall M.
    Hampson, Hannah
    Hillier, Alison
    Ho, Koc-Kan
    Kiczun, Michael
    Kingsbury, Celia
    Kultgen, Steven G.
    Littlewood, Peter T. A.
    Lusher, Scott J.
    MacDonald, Susan
    McIntosh, Lorraine
    McIntyre, Theresa
    Mistry, Ashvin
    Morphy, J. Richard
    Nimz, Olaf
    Ohlmeyer, Michael
    Pick, Jack
    Rankovic, Zoran
    Sherborne, Brad
    Smith, Alasdair
    Speake, Michael
    Spinks, Gayle
    Thomson, Fiona
    Watson, Lynn
    Weston, Mark
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (01) : 137 - 140
12345